Heart disease risk in people newly diagnosed with type 2 diabetes in Southeast Asia
Reviews past records to describe heart disease risk in newly diagnosed type 2 diabetes.
Plain-language title generated from the registry record
Registry title: A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Participants
Key facts
- Where
- Surabaya and Tangerang, IndonesiaSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 70 years old?
Source: NCT07532863, who can take part
Where in Indonesia
- Siloam Hospitals SurabayaSurabaya, IndonesiaEnrolling by invitation
- Siloam Hospitals Lippo VillageTangerang, IndonesiaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07532863
- Record updated
- 28 July 2026
- Original description
The purpose of the study is to investigate the cardiovascular disease (CVD) risk profile among participants newly diagnosed with type 2 diabetes mellitus (T2DM) in Southeast Asia (CRISTAL SEA). It's a retrospective chart-review across five Southeast Asian countries to characterize newly diagnosed T2DM participants and how their CVD risk is distributed, using data from the year before diagnosis and roughly the first year after diagnosis.Read full original descriptionShow less
A Retrospective Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus Participants in Southeast Asia
The purpose of the study is to investigate the cardiovascular disease (CVD) risk profile among participants newly diagnosed with type 2 diabetes mellitus (T2DM) in Southeast Asia (CRISTAL SEA). It's a retrospective chart-review across five Southeast Asian countries to characterize newly diagnosed T2DM participants and how their CVD risk is distributed, using data from the year before diagnosis and roughly the first year after diagnosis.
Inclusion: Aged greater than equal to (≥) 40 and less than (<) 70 years; Male or female; Newly diagnosed with T2DM and initiated on anti-hyperglycemic treatment between 1 January 2022 and 31 December 2023.
Exclusion: Prescribed with any anti-hyperglycemic medications before first diagnosis of T2DM; T1DM or gestational diabetes; With pre-existing atherosclerotic CVD including coronary heart disease, stroke, transient ischemic attack, or peripheral artery disease; If any exclusion criterion is met, the participant will be excluded from the study; Pregnant women; Died within 12 months after first diagnosis of T2DM; Lost to follow-up i.e., no visit 12 months (± 3 months) after first diagnosis of T2DM.